Pedro Nam, MD
Adolescent Medicine · Loxaharchee, FLNPI 1679673743
Payments from drug & device makers
Across 544 payments — averaging $176.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$83K
- AstraZeneca$6K
- AbbVie$1K
- Pfizer$1K
- Lilly USA, LLC$1K
- Novo Nordisk$880
- plus $3K from 38 others
Across 4 payments — averaging $10,690 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$43K
What the payments were for
- Food & beverage$8,50899%
- Education$971%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$125
How this compares
$96,160 in reported general payments places this provider in the 95th percentile of 113 adolescent medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 114 | $118,213 |
| EliquisApixaban | 104 | $111,054 |
| FarxigaDapagliflozin Propanediol | 88 | $89,863 |
| LinzessLinaclotide | 61 | $59,671 |
| MounjaroTirzepatide | 56 | $59,352 |
| XareltoRivaroxaban | 51 | $51,217 |
| JardianceEmpagliflozin | 32 | $43,422 |
| JanuviaSitagliptin Phosphate | 31 | $38,703 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $32,914 |
| RybelsusSemaglutide | 20 | $27,484 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $23,549 |
| TrulicityDulaglutide | 18 | $20,761 |
| EntrestoSacubitril/Valsartan | 17 | $19,783 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $13,605 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $6,760 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $880 | $145,698134 claims |
| PfizerEliquis | $1,246 | $111,054104 claims |
| AstraZenecaFarxiga, Symbicort | $5,562 | $96,622114 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,022 | $80,11374 claims |
| AbbVieLinzess, Synthroid | $1,349 | $61,81982 claims |
| Johnson & JohnsonXarelto | $245 | $51,21751 claims |
| Boehringer IngelheimJardiance | $64 | $43,42232 claims |
| MerckJanuvia | $37 | $38,70331 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $281 | $37,77559 claims |
| NovartisEntresto | $15 | $19,78317 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $12 | $2,425241 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 113 adolescent medicine providers in Florida.
Other adolescent medicine in Loxaharchee
- Ana Roig CantisanoMiami$2.2M
- Jose AcostaMiami Gardens$568K
- Amy WeissTampa$139K
- Diana VargasMiami$94K
- Lonna GordonOrlando$92K
- Adriana CastroMiami$70K
- Rajeev RajaniNaples$6K
- Meera BeharryFort Pierce$5K
- Nasin David RiveraOrlando$4K
- Heather Elizondo VegaWinter Garden$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.